0001104659-23-105925.txt : 20231002
0001104659-23-105925.hdr.sgml : 20231002
20231002163908
ACCESSION NUMBER: 0001104659-23-105925
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230928
FILED AS OF DATE: 20231002
DATE AS OF CHANGE: 20231002
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fitzgerald Thomas A
CENTRAL INDEX KEY: 0001854168
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40363
FILM NUMBER: 231300246
MAIL ADDRESS:
STREET 1: C/O TRANSCODE THERAPEUTICS, INC.
STREET 2: 6 LIBERTY SQUARE, #2382
CITY: BOSTON
STATE: MA
ZIP: 02109
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Transcode Therapeutics, Inc.
CENTRAL INDEX KEY: 0001829635
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 811065054
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6 LIBERTY SQUARE
STREET 2: #2382
CITY: BOSTON
STATE: MA
ZIP: 02109
BUSINESS PHONE: 857-301-6857
MAIL ADDRESS:
STREET 1: 6 LIBERTY SQUARE
STREET 2: #2382
CITY: BOSTON
STATE: MA
ZIP: 02109
4
1
tm2327413d2_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-09-28
0
0001829635
Transcode Therapeutics, Inc.
RNAZ
0001854168
Fitzgerald Thomas A
C/O TRANSCODE THERAPEUTICS, INC.
6 LIBERTY SQUARE, #2382
BOSTON
MA
02109
1
1
0
0
Chief Financial Officer
0
Common Stock
2023-09-28
4
P
0
49350
0.51
A
56318
D
Represents shares acquired pursuant to an underwritten public offering of common stock by the Issuer.
Reported amount reflects a 1-for-20 reverse stock split of the Issuer's common stock, which became effective as of May 22, 2023.
/s/ Thomas A. Fitzgerald
2023-10-02